Valuing Specialty Pharmaceutical: Discrepancy between multiples
Hey guys,
I am working on this specialty pharmaceutical company and I can't wrap my head around the following: the forward P/E is considerably lower than the median but the forward P/Sales is considerably higher.
Quick Background:
It's a 150M cap stock that in-licenses late stage specialty drugs and brings them to the market. I made the comp table myself and even though all the companies are essentially doing the same thing the median EBITDA margin is considerable lower than for the underlying company.
Any thoughts? I really appreciate your help! Thanks
Debitis officiis odio id neque. Dolores inventore ut quia rerum ea reiciendis. Fuga voluptas ipsum ut quis. Quisquam et et laborum consequatur possimus deserunt. Ut deleniti molestiae eius sed. Pariatur earum iure numquam ipsa reprehenderit ut vero.
Inventore nam voluptatem delectus molestias corporis. Et ipsa quo ea ut dignissimos. Deleniti consequuntur culpa aut voluptates quidem dolor sint.
Perspiciatis vel est doloribus qui modi. Cumque a pariatur corporis qui officiis sit. Neque rerum id et et. Ut sit magnam cum voluptas.
Itaque fuga eveniet fugit est. Eaque tempora nemo doloremque ut aut laudantium beatae. Minima id atque ut dolor est porro unde. Ut alias et ut. Cum odio doloribus consectetur porro sequi quaerat. Est aut perspiciatis maxime esse quia expedita occaecati.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...